Atrix Begins Enrollment of Phase III Study for Atrisone(TM), A Topical Acne Treatment

Apr 18, 2001, 01:00 ET from Atrix Laboratories, Inc.

    FORT COLLINS, Colo., April 18 /PRNewswire/ -- Atrix Laboratories, Inc.
 (Nasdaq:   ATRX) announced today it has begun patient enrollment of a
 multi-center Phase III clinical trial for Atrisone(TM), a novel product for
 the topical treatment of moderate to severe acne.
     Atrisone combines the pharmaceutical dapsone with Atrix's proprietary drug
 delivery system, SMP(TM).  Dapsone is a potent antibiotic with a separate
 anti-inflammatory mode of action.  The primary advantage of the SMP technology
 is that it allows highly water insoluble drugs, such as dapsone, to be
 delivered topically.
     "Dermatologists are seeking a safe and effective treatment for moderate to
 severe acne," said David R. Bethune, Atrix's chairman and chief executive
 officer.  "Many oral pharmaceuticals are effective but have side effects.
 Topical products have a better safety profile but often are less effective.
 Results from our Phase I/II dose-ranging study suggest that Atrisone may offer
 the power of a systemic medication with the safety of a topical."
     Last month, Atrix presented results from its Phase I/II clinical trials at
 the 59th Annual Meeting of the American Academy of Dermatology (AAD) in
 Washington D.C.  The data showed maximum blood concentration of dapsone (5%)
 administrated topically twice a day was over 600 times lower than the systemic
 "safety concern" level for oral administration of dapsone.  In addition, while
 this was not an efficacy study and not powered to demonstrate statistical
 significance, Atrisone appeared to reduce both inflammatory and
 non-inflammatory lesions by about 50 percent over the 28-day duration of this
 study.
 
     Atrix Laboratories, Inc. is an emerging specialty pharmaceutical company
 focused on advanced drug delivery.  With five unique patented technologies,
 Atrix is currently developing a diverse portfolio of proprietary products,
 including oncology, pain management, and dermatology products.  The company
 also partners with large pharmaceutical and biotechnology companies to apply
 its proprietary technologies to new chemical entities or to extend the patent
 life of existing products.  Atrix has strategic alliances with several
 pharmaceutical companies including recent collaborations with Pfizer, Elan
 Corporation Plc, Sanofi-Synthelabo and the Novartis company - Geneva
 Pharmaceuticals, to use its drug delivery technologies and expertise in the
 development of new products.  Additional information is available on the Atrix
 Laboratories, Inc.  Web site at http://www.atrixlabs.com.
 
     Statements contained in this press release, which are not historical
 facts, are forward-looking statements, as the term is defined in the Private
 Securities Litigation Reform Act of 1995.  Such forward-looking statements are
 subject to risks and uncertainties which can cause actual results to differ
 materially from those currently anticipated, due to a number of factors, which
 include, but are not limited to, product demand, pricing, market acceptance,
 changing economic conditions, risks in product and technology development, the
 effect of the company's accounting policies and other risk factors discussed
 in documents filed by the company with the Securities and Exchange Commission
 from time to time.
 
     For further information please contact Danette R.M. Meyer, Ph.D., Director
 of Investor Relations of Atrix Laboratories, Inc., 970-482-5868,
 Dmeyer@atrixlab.com; or investor relations, Robert Jaffe of Pondel/Wilkinson
 MS&L, 310-207-9300, rjaffe@pondel.com, for Atrix Laboratories, Inc.
 
 

SOURCE Atrix Laboratories, Inc.
    FORT COLLINS, Colo., April 18 /PRNewswire/ -- Atrix Laboratories, Inc.
 (Nasdaq:   ATRX) announced today it has begun patient enrollment of a
 multi-center Phase III clinical trial for Atrisone(TM), a novel product for
 the topical treatment of moderate to severe acne.
     Atrisone combines the pharmaceutical dapsone with Atrix's proprietary drug
 delivery system, SMP(TM).  Dapsone is a potent antibiotic with a separate
 anti-inflammatory mode of action.  The primary advantage of the SMP technology
 is that it allows highly water insoluble drugs, such as dapsone, to be
 delivered topically.
     "Dermatologists are seeking a safe and effective treatment for moderate to
 severe acne," said David R. Bethune, Atrix's chairman and chief executive
 officer.  "Many oral pharmaceuticals are effective but have side effects.
 Topical products have a better safety profile but often are less effective.
 Results from our Phase I/II dose-ranging study suggest that Atrisone may offer
 the power of a systemic medication with the safety of a topical."
     Last month, Atrix presented results from its Phase I/II clinical trials at
 the 59th Annual Meeting of the American Academy of Dermatology (AAD) in
 Washington D.C.  The data showed maximum blood concentration of dapsone (5%)
 administrated topically twice a day was over 600 times lower than the systemic
 "safety concern" level for oral administration of dapsone.  In addition, while
 this was not an efficacy study and not powered to demonstrate statistical
 significance, Atrisone appeared to reduce both inflammatory and
 non-inflammatory lesions by about 50 percent over the 28-day duration of this
 study.
 
     Atrix Laboratories, Inc. is an emerging specialty pharmaceutical company
 focused on advanced drug delivery.  With five unique patented technologies,
 Atrix is currently developing a diverse portfolio of proprietary products,
 including oncology, pain management, and dermatology products.  The company
 also partners with large pharmaceutical and biotechnology companies to apply
 its proprietary technologies to new chemical entities or to extend the patent
 life of existing products.  Atrix has strategic alliances with several
 pharmaceutical companies including recent collaborations with Pfizer, Elan
 Corporation Plc, Sanofi-Synthelabo and the Novartis company - Geneva
 Pharmaceuticals, to use its drug delivery technologies and expertise in the
 development of new products.  Additional information is available on the Atrix
 Laboratories, Inc.  Web site at http://www.atrixlabs.com.
 
     Statements contained in this press release, which are not historical
 facts, are forward-looking statements, as the term is defined in the Private
 Securities Litigation Reform Act of 1995.  Such forward-looking statements are
 subject to risks and uncertainties which can cause actual results to differ
 materially from those currently anticipated, due to a number of factors, which
 include, but are not limited to, product demand, pricing, market acceptance,
 changing economic conditions, risks in product and technology development, the
 effect of the company's accounting policies and other risk factors discussed
 in documents filed by the company with the Securities and Exchange Commission
 from time to time.
 
     For further information please contact Danette R.M. Meyer, Ph.D., Director
 of Investor Relations of Atrix Laboratories, Inc., 970-482-5868,
 Dmeyer@atrixlab.com; or investor relations, Robert Jaffe of Pondel/Wilkinson
 MS&L, 310-207-9300, rjaffe@pondel.com, for Atrix Laboratories, Inc.
 
 SOURCE  Atrix Laboratories, Inc.